Sarepta Therapeutics Inc. (NASDAQ:SRPT)’s share price rose 2.2% during mid-day trading on Tuesday . The stock traded as high as $21.73 and last traded at $21.42, with a volume of 1,099,296 shares trading hands. The stock had previously closed at $20.95.

A number of equities analysts have weighed in on SRPT shares. WBB Securities restated a “buy” rating and set a $40.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, March 30th. Needham & Company LLC restated a “buy” rating and set a $53.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 22nd. Oppenheimer Holdings Inc. restated a “buy” rating and set a $60.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, April 21st. Robert W. Baird restated a “buy” rating and set a $23.00 price objective (down from $47.00) on shares of Sarepta Therapeutics in a research report on Saturday, April 23rd. Finally, Vetr cut shares of Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $17.92 price objective for the company. in a research report on Monday, April 25th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. Sarepta Therapeutics has a consensus rating of “Hold” and a consensus price target of $24.17.

The firm’s market capitalization is $982.31 million. The company’s 50-day moving average is $19.26 and its 200-day moving average is $18.23.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, May 5th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.15. During the same period last year, the company posted ($1.15) EPS. On average, equities research analysts expect that Sarepta Therapeutics Inc. will post ($4.48) EPS for the current year.

Several hedge funds and institutional investors have recently added to or reduced their stakes in SRPT. Jennison Associates LLC increased its position in Sarepta Therapeutics by 463.6% in the fourth quarter. Jennison Associates LLC now owns 838,629 shares of the company’s stock valued at $32,354,000 after buying an additional 689,831 shares during the period. Creative Planning increased its position in Sarepta Therapeutics by 95.7% in the fourth quarter. Creative Planning now owns 52,950 shares of the company’s stock valued at $2,043,000 after buying an additional 25,900 shares during the period. ProShare Advisors LLC increased its position in Sarepta Therapeutics by 20.5% in the fourth quarter. ProShare Advisors LLC now owns 42,922 shares of the company’s stock valued at $1,656,000 after buying an additional 7,301 shares during the period. California State Teachers Retirement System increased its position in Sarepta Therapeutics by 9.7% in the fourth quarter. California State Teachers Retirement System now owns 82,932 shares of the company’s stock valued at $3,200,000 after buying an additional 7,300 shares during the period. Finally, Rhumbline Advisers increased its position in Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock valued at $1,841,000 after buying an additional 6,615 shares during the period.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.